Trial Profile
A Phase 1, Single-Dose, Randomized, Cross-Over, Relative Bioavailability, and Food Effect Study of Ipatasertib (GDC-0068) in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2022
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary) ; Ipatasertib (Primary)
- Indications Breast cancer; Endometrial cancer; Gastrointestinal cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Genentech
- 01 Dec 2021 Results assessing single- and multiple-dose pharmacokinetics (PK), CYP3A inhibition potential of ipatasertib, and effect of food on PK of ipatasertib in patients with refractory solid tumors and a dedicated food effect assessment in healthy subjects published in the Cancer Chemotherapy and Pharmacology
- 01 Dec 2015 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
- 02 Sep 2015 New trial record